Erratum: Treatment strategies for coronary in-stent restenosis: Systematic review and hierarchical Bayesian network meta-analysis of 24 randomised trials and 4880 patients (BMJ (Online) (2015) 351 (h5392) DOI: 10.1136/bmj.h5392);Treatment strategies for coronary in-stent restenosis: Systematic review and hierarchical Bayesian network meta-analysis of 24 randomised trials and 4880 patients

The BMJ

Volumn 351, Issue , 2015, Pages

  Giacoppo, Daniele ^a   Gargiulo, Giuseppe ^a   Aruta, Patrizia ^a   Capranzano, Piera ^a,b   Tamburino, Corrado ^a,b   Capodanno, Davide ^a,b  

^a Ferrarotto Hospital   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADVERSE OUTCOME; BALLOON; BARE METAL STENT; BAYES THEOREM; BRACHYTHERAPY; CLINICAL EFFECTIVENESS; CUTTING BALLOON; DRUG COATED BALLOON; DRUG ELUTING STENT; FOLLOW UP; HEART DEATH; HEART INFARCTION; HUMAN; IN-STENT RESTENOSIS; MATERIAL COATING; PRIORITY JOURNAL; PROBABILITY; REVASCULARIZATION; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; ROTATIONAL ATHERECTOMY; SENSITIVITY ANALYSIS; STENT THROMBOSIS; SYSTEMATIC REVIEW; ADVERSE EFFECTS; CORONARY RESTENOSIS; HEART MUSCLE REVASCULARIZATION; META ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); STENT;

IMMUNOSUPPRESSIVE AGENT;

BAYES THEOREM; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYOCARDIAL REVASCULARIZATION; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STENTS;

EID: 84949033496     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.h6364     Document Type: Erratum

References (58)

1. Stefanini GG, Holmes DR Jr. Drug-eluting coronary-artery stents. N Engl J Med 2013;368:254-65.
2. Cassese S, Byrne RA, Tada T, et al. Incidence and predictors of restenosis after coronary stenting in 10 004 patients with surveillance angiography. Heart 2014;100:153-.
3. Mauri L, Silbaugh TS, Wolf RE, et al. Long-term clinical outcomes after drug-eluting and bare-metal stenting in massachusetts. Circulation 2008;118:1817-27.
4. Alfonso F, Byrne RA, Rivero F, Kastrati A. Current treatment of in-stent restenosis. J Am Coll Cardiol 2014;63:2659-73.
5. Mehran R, Mintz GS, Popma JJ, et al. Mechanisms and results of balloon angioplasty for the treatment of in-stent restenosis. Am J Cardiol 1996;78:618-22.
6. Kim YH, Lee BK, Park DW, et al. Comparison with conventional therapies of repeated sirolimus-eluting stent implantation for the treatment of drug-eluting coronary stent restenosis. Am J Cardiol 2006;98:1451-4.
7. Alfonso F, Cequier A, Angel J, et al. Restenosis intra-stent balloon angioplasty versus elective stenting I. Am Heart J 2006;151:e681-9.
8. Kastrati A, Mehilli J, von Beckerath N, et al. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: A randomised controlled trial. JAMA 2005;293:165-71.
9. Tagliareni F, La Manna A, Saia F, Marzocchi A, Tamburino C. Long-term clinical follow-up of drug-eluting stent restenosis treatment: retrospective analysis from two high volume catheterisation laboratories. EuroIntervention 2010;5:703-8.
10. Rathore S, Kinoshita Y, Terashima M, et al. A comparison of clinical presentations, angiographic patterns and outcomes of in-stent restenosis between bare-metal stents and drug-eluting stents. EuroIntervention 2010;5:841-6.
11. Dangas GD, Claessen BE, Mehran R, et al. Clinical outcomes following stent thrombosis occurring in-hospital versus out-of-hospital: Results from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial. J Am Coll Cardiol 2012;59:1752-9.
12. Habara S, Mitsudo K, Kadota K, et al. Effectiveness of paclitaxeleluting balloon catheter in patients with sirolimus-eluting stent restenosis. JACC Cardiovasc Interv 2011;4:149-54.
13. Scheller B, Hehrlein C, Bocksch W, et al. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med 2006;355:2113-24.
14. Unverdorben M, Vallbracht C, Cremers B, et al. Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis. Circulation 2009;119:2986-94.
15. Dangas GD, Claessen BE, Caixeta A, Sanidas EA, Mintz GS, Mehran R. In-stent restenosis in the drug-eluting stent era. J Am Coll Cardiol 2010;56:1897-907.
16. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004;23:3105-24.
17. Salanti G, Higgins JP, Ades AE, Ioannidis JP. Evaluation of networks of randomised trials. Stat Methods Med Res 2008;17:279-301.
18. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. BMJ 2009;339:b2535.
19. Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: Checklist and explanations. Ann Intern Med 2015;162:777-84.
20. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions 5.1.0 [updated March 2011]. www.cochranehandbook.org.
21. Mehran R, Dangas G, Abizaid AS, et al. Angiographic patterns of in-stent restenosis: Classification and implications for long-term outcome. Circulation 1999;100:1872-8.
22. Cutlip DE, Windecker S, Mehran R, et al. Academic Research Consortium. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation 2007;115:2344-51.
23. Mauri L, Orav EJ, O'Malley AJ, et al. Relationship of late loss in lumen diameter to coronary restenosis in sirolimus-eluting stents. Circulation 2005;111:321-7.
24. Mauri L, Orav EJ, Candia SC, Cutlip DE, Kuntz RE. Robustness of late lumen loss in discriminating drug-eluting stents across variable observational and randomized trials. Circulation 2005;112:2833-9.
25. Lu G, Ades AE. Assessing evidence inconsistency in mixed treatment comparisons. J Am Stat Assoc 2006;447-59.
26. Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in mixed treatment comparison meta-analysis. Stat Med 2010;29:932-44.
27. Biondi-Zoccai G, Abbate A, Benedetto U, Palmerini T, D'Ascenzo F, Frati G. Network meta-analysis for evidence synthesis: what is it and why is it posed to dominate cardiovascular decision making? Int J Cardiol 2015;182:309-14.
28. Dias S, Sutton AJ, Ades AE, Welton NJ. Evidence synthesis for decision making 2: A generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med Decis Making 2013;33:607-17.
29. Dias S, Welton NJ, Sutton AJ, Caldwell DM, Lu G, Ades AE. Evidence synthesis for decision making 4: Inconsistency in networks of evidence based on randomized controlled trials. Med Decis Making 2013;33:641-56.
30. Mills EJ, Thorlund K, Ioannidis JP. Demystifying trial networks and network meta-analysis. BMJ 2013;346:f2914.
31. Lambert PC, Sutton AJ, Burton PR, Abrams KR, Jones DR. How vague is vague? A simulation study of the impact of the use of vague prior distributions in MCMC using WinBUGS. Stat Med 2005;24:2401-28.
32. Brooks SP, Gelman A. General methods for monitoring convergence of iterative simulations. J Comput Graph Stat 1998;7:434-55.
33. Salanti G, Ades A, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment metaanalysis: An overview and tutorial. J Clin Epidemiol 2011;64:163-71.
34. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88.
35. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
36. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Introduction to meta-analysis. John Wiley & Sons, 2009.
37. Chaimani A, Higgins JP, Mavridis D, Spyridonos P, Salanti G. Graphical tools for network meta-analysis in stata. PloS One 2013;8:e76654.
38. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Contourenhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry. J Clin Epidemiol 2008;61:991-6.
39. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Comparison of two methods to detect publication bias in meta-analysis. JAMA 2006; 295:676-80.
40. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
41. Lee JM, Park J, Kang J, et al. Comparison among drug-eluting balloon, drug-eluting stent, and plain balloon angioplasty for the treatment of in-stent restenosis: A network meta-analysis of 11 randomised, controlled trials. JACC Cardiovascular Intv 2015;8:382-94.
42. Hoffmann R, Mintz GS, Dussaillant GR, et al. Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. Circulation 1996;94:1247-54.
43. Shiran A, Mintz GS, Waksman R, et al. Early lumen loss after treatment of in-stent restenosis: An intravascular ultrasound study. Circulation 1998;98:200-3.
44. Park SJ, Kang SJ, Virmani R, Nakano M, Ueda Y. In-stent neoatherosclerosis: A final common pathway of late stent failure. J Am Coll Cardiol 2012;59:2051-7.
45. Alfonso F, Sandoval J, Perez-Vizcayno MJ, et al. Mechanisms of balloon angioplasty and repeat stenting in patients with drug-eluting in-stent restenosis. Int J Cardiol 2015;178:213-20.
46. Elezi S, Kastrati A, Neumann FJ, Hadamitzky M, Dirschinger J, Schomig A. Vessel size and long-term outcome after coronary stent placement. Circulation 1998;98:1875-80.
47. Kornowski R, Mintz GS, Kent KM, et al. Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia. A serial intravascular ultrasound study. Circulation 1997;95:1366-9.
48. Cortese B, Berti S, Biondi-Zoccai G, et al. Drug-coated balloon treatment of coronary artery disease: A position paper of the Italian Society of Interventional Cardiology. Catheter Cardiovasc Interv 2014;83:427-35.
49. Habara S, Kadota K, Kanazawa T, et al. Paclitaxel-coated balloon catheter compared with drug-eluting stent for drug-eluting stent restenosis in routine clinical practice. EuroIntervention 2015;10, doi:10.4244/EIJY15M02-09.
50. Kubo S, Kadota K, Otsuru S, et al. Everolimus-eluting stent implantation versus repeat paclitaxel-coated balloon angioplasty for recurrent in-stent restenosis lesion caused by paclitaxel-coated balloon failure. EuroIntervention 2015;10:e1- e8.
51. Windecker S, Kolh P, Alfonso F, et al. The task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Guidelines on myocardial revascularization. Eur Heart J 2014;35:2541-619.
52. Mehran R, Dangas G, Abizaid A, et al. Treatment of focal in-stent restenosis with balloon angioplasty alone versus stenting: short- And long-term results. Am Heart J 2001;141:610-4.
53. Alfonso F, Zueco J, Cequier A, et al. A randomised comparison of repeat stenting with balloon angioplasty in patients with in-stent restenosis. J Am Coll Cardiol 2003;42:796-805.
54. Tomey MI, Kini AS, Sharma SK. Current status of rotational atherectomy. JACC Cardiovasc Intv 2014;7:345-53.
55. Albiero R, Silber S, Di Mario C, et al. Cutting balloon versus conventional balloon angioplasty for the treatment of in-stent restenosis: Results of the restenosis cutting balloon evaluation trial (RESCUT). J Am Coll Cardiol 2004;43:943-9.
56. Grasso C, Attizzani GF, Patanè M, Ohno Y, Capodanno D, Tamburino C. First-in-human description of everolimus-eluting bioabsorbable vascular scaffold implantation for the treatment of drug-eluting stent failure: Insights from optical coherence tomography. Int J Cardiol 2013;168:4490-1.
57. Alfonso F, Nuccio J, Cuevas C, Cardenas A, Gonzalo N, Jimenez- Quevedo P. Treatment of coronary in-stent restenosis with bioabsorbable vascular scaffolds. J Am Coll Cardiol 2014;63:2875.
58. Iqbal J, Onuma Y, Ormiston J, Abizaid A, Waksman R, Serruys P. Bioresorbable scaffolds: Rationale, current status, challenges, and future. Eur Heart J 2014;35:765-76.